Lytix Biopharma ASA Income Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	32.62	22.59	24.34	20.33	30.37
Depreciation & Amortization Expenses	1	0.92	0.96	0.92	0.45
Research & Development	13.8	72.57	63.17	45.61	23.74
Other Operating Expenses	16.6	10.96	12.3	9.84	12.92
Total Operating Expenses	64.03	107.03	100.78	76.7	67.48
Operating Income	-64.03	-95.9	-96.79	-65.67	-47.99
Interest Income	4.26	2.18	8.95	9.84	0.14
Interest Expense	-0.22	-0.55	-0.06	-0.24	-0.24
Total Non-Operating Income (Expense)	4.05	1.63	8.89	9.6	-0.09
Pretax Income	-59.98	-94.27	-87.9	-56.07	-48.08
Net Income	-59.98	-94.27	-87.9	-56.07	-48.08
Net Income to Common	-59.98	-94.27	-87.9	-56.07	-48.08
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	68	54	40	40	33
Shares Outstanding (Diluted)	68	54	40	40	33
Shares Change	26.05%	35.05%	1.01%	19.50%	26.57%
EPS (Basic)	-0.88	-1.74	-2.19	-1.41	-1.45
EPS (Diluted)	-0.88	-1.74	-2.19	-1.41	-1.45
EPS Growth	-	-	-	-	-
Free Cash Flow	-59.85	-70.37	-96.02	-52.78	-44.61
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Per Share	-0.88	-1.30	-2.40	-1.33	-1.34
EBITDA	-63.02	-94.98	-95.82	-64.75	-47.53
EBIT	-64.03	-95.9	-96.79	-65.67	-47.99